Statin Use in Patients With Cancer: Drug Interaction and Statin Usage
Authors' conclusion
Statin-oncology agent DDIs are relatively common but rarely is statin use contraindicated. Frequency of statins use varies according to cancer type.
Study context
- Population
- Recently approved oncology agents and 5 commonly prescribed statins; patients with cancer
- Participants
- 138 oncology agents
- Outcome
- DDIs between statins and oncology agents
Methodological detailsFDA oncology approvals June 2019–June 2024, UpToDate Lexidrug screening, scoping review of 20 observational studies
- FDA oncology approvals June 2019–June 2024
- UpToDate Lexidrug screening
- Scoping review of 20 observational studies
Main finding
As reported in the abstract
Oncology agents with drug-drug interactions (DDIs) with statins
33 (23.9%) of 138
Simvastatin: highest interaction rate
22%
30/138
Pravastatin: fewest interactions
4%
5/138
Interactions classified level C (requiring monitoring)
88%, 71/81
Observational data: associations, not effects.
Further findings
Statin use by cancer type
- Prostate cancer
- 53%, 57,926/109,140
- Lung cancer
- 32%, 1,403/4,344
- Liver cancer
- 8%, 3,100/39,722
- Breast cancer
- 10%, 1,519/15,078
Original publication
Statin Use in Patients With Cancer: Drug Interaction and Statin Usage. JACC Adv. Published 21 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →